-- 北美再生能源專案所有者、營運商和開發商Revolve Renewable Power（股票代碼：REVV.CN）週三宣布，已簽署最終協議，將在墨西哥開發九個太陽能項目，總裝置容量達2.4兆瓦，進一步拓展其分散式電力解決方案業務。 該公司在聲明中表示，這些新項目將併入Revolve目前在墨西哥擁有的6.05兆瓦營運資產，以及與RER Energy合作建設的2.8兆瓦（16個項目）在建項目（已於2026年3月5日宣布）。 聲明也補充道，預計這些新項目每年將產生37萬至84.3萬美元的收入，年度EBITDA預計在29.6萬至67.6萬美元之間，主要來自向商業客戶售電。 「最新的專案組合體現了我們在墨西哥分散式發電領域看到的加速成長，」執行長 Mikeke Clark 表示。 「這家製造企業客戶將長期節省電費，並降低營運成本。對於 Revolve 而言，我們正在擴大以穩定的 20年購電協議為支撐的創收資產組合。 該公司還在墨西哥伊拉普阿託為一家商業客戶啟動了一個獨立的 490 千瓦分散式太陽能發電專案。該 490 千瓦工程預計將於 2026 年 5 月底完工。 REVV 的股票昨日在加拿大證券交易所 (CSE) 的股價持平於 0.175 美元。
Related Articles
Treasury
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
$$CXY
Australia
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
$VICR
Australia
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%
$BMRN$FOLD